<DOC>
	<DOCNO>NCT01941511</DOCNO>
	<brief_summary>This clinical evaluation QT/QTc interval prolongation proarrhythmic potential GMI-1070 African-American Adult subject . This conducted part standard drug development .</brief_summary>
	<brief_title>A Study Evaluate Effect IV Doses GMI-1070 Qtc Intervals Healthy African-American Adult Subjects</brief_title>
	<detailed_description>Safety</detailed_description>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Healthy AfricanAmerican male and/or female subject nonchildbearing potential age 18 55 year , inclusive . Pregnant female ; breastfeed female ; female childbearing potential . Males unwilling unable use 2 highly effective method contraception duration study start least 14 day prior first dose investigational product least 28 day last dose investigational product . Non AfricanAmerican . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>QTc</keyword>
	<keyword>African-American</keyword>
	<keyword>GMI-1070</keyword>
	<keyword>QT/QTc interval prolongation</keyword>
</DOC>